CEOs from leading AI companies, including OpenAI, Anthropic, Microsoft AI, and Google DeepMind, have collaborated with biotechnology experts to advocate for new legislation in the United States aimed at regulating synthetic DNA purchases. This synthetic DNA, which can be easily ordered online, has facilitated advancements in vaccine development and research but also poses significant risks if misused by malicious actors to recreate dangerous pathogens. The letter emphasizes the necessity for mandatory safety screenings and record-keeping to deter potential misuse and enhance traceability of suspicious orders. The authors highlight that AI advancements have lowered the barriers for bad actors, as AI systems can now outperform experienced virologists in technical queries. In parallel, the European Commission is working on the EU Biotech Act to regulate biotechnology and biomanufacturing sectors, addressing similar biosecurity risks and proposing frameworks for customer verification and reporting suspicious activities.